Towards a revised nomenclature for P1 and P2 receptors.
作者信息
Fredholm B B, Abbracchio M P, Burnstock G, Dubyak G R, Harden T K, Jacobson K A, Schwabe U, Williams M
机构信息
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
出版信息
Trends Pharmacol Sci. 1997 Mar;18(3):79-82. doi: 10.1016/s0165-6147(96)01038-3.
Abstract
摘要
相似文献
1
Towards a revised nomenclature for P1 and P2 receptors.迈向P1和P2受体的修订命名法。
Trends Pharmacol Sci. 1997 Mar;18(3):79-82. doi: 10.1016/s0165-6147(96)01038-3.
2
Nomenclature and classification of purinoceptors.嘌呤受体的命名与分类
Pharmacol Rev. 1994 Jun;46(2):143-56.
3
Receptors for adenine nucleotides and nucleosides: subclassification, distribution, and molecular characterization.腺嘌呤核苷酸和核苷的受体：亚分类、分布及分子特征
Pharmacol Rev. 1994 Dec;46(4):449-66.
4
Purinergic receptors.嘌呤能受体。
Pol J Pharmacol. 1996 Sep-Oct;48(5):457-65.
5
The past, present and future of purine nucleotides as signalling molecules.嘌呤核苷酸作为信号分子的过去、现在与未来
Neuropharmacology. 1997 Sep;36(9):1127-39. doi: 10.1016/s0028-3908(97)00125-1.
6
Purinoceptors in the nervous system.神经系统中的嘌呤受体。
Pharmacol Toxicol. 1995 Apr;76(4):228-39. doi: 10.1111/j.1600-0773.1995.tb00135.x.
7
Mitogenic signaling from P1 and P2 purinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures.在人胎儿星形胶质细胞培养物中，从P1和P2嘌呤能受体到丝裂原活化蛋白激酶的促有丝分裂信号传导。
Neurosci Lett. 1998 Feb 20;242(3):159-62. doi: 10.1016/s0304-3940(98)00067-6.
8
9
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.国际基础和临床药理学联合会. LXXXI. 腺苷受体的命名和分类-更新。
Pharmacol Rev. 2011 Mar;63(1):1-34. doi: 10.1124/pr.110.003285. Epub 2011 Feb 8.
10
Purinoceptors: are there families of P2X and P2Y purinoceptors?嘌呤受体：是否存在P2X和P2Y嘌呤受体家族？
Pharmacol Ther. 1994;64(3):445-75. doi: 10.1016/0163-7258(94)00048-4.
引用本文的文献
1
Purinergic System Transcript Changes in the Dorsolateral Prefrontal Cortex in Suicide and Major Depressive Disorder.自杀和重度抑郁症患者背外侧前额叶皮质中嘌呤能系统转录本的变化
Int J Mol Sci. 2025 Feb 20;26(5):1826. doi: 10.3390/ijms26051826.
2
Ectonucleotidase inhibitors: targeting signaling pathways for therapeutic advancement-an in-depth review.外核苷酸酶抑制剂：靶向信号通路以促进治疗进展——深入综述
Purinergic Signal. 2025 Apr;21(2):221-265. doi: 10.1007/s11302-024-10031-0. Epub 2024 Jul 3.
3
Probing Adenosine and P2 Receptors: Design of Novel Purines and Nonpurines as Selective Ligands.探索腺苷和P2受体：新型嘌呤和非嘌呤作为选择性配体的设计
Drug Dev Res. 2001 Jan-Feb;52(1-2):178-186. doi: 10.1002/ddr.1113.
4
Two Distinct P2Y Receptors Are Involved in Purine- and Pyrimidine-Evoked Ca Elevation in Mammalian Brain Astrocytic Cultures.两种不同的P2Y受体参与嘌呤和嘧啶引起的哺乳动物脑星形胶质细胞培养物中的钙离子升高。
Drug Dev Res. 2001 Jan-Feb;52(1-2):122-132. doi: 10.1002/ddr.1106.
5
Astrocyte-targeted siRNA delivery by adenosine-functionalized LNP in mouse TBI model.在小鼠创伤性脑损伤模型中，通过腺苷功能化脂质纳米颗粒进行星形胶质细胞靶向的小干扰RNA递送。
Mol Ther Nucleic Acids. 2023 Oct 20;34:102065. doi: 10.1016/j.omtn.2023.102065. eCollection 2023 Dec 12.
6
A2B Adenosine Receptor in Idiopathic Pulmonary Fibrosis: Pursuing Proper Pit Stop to Interfere with Disease Progression.特发性肺纤维化中的 A2B 腺苷受体：寻找合适的干预点以阻止疾病进展。
Int J Mol Sci. 2023 Feb 23;24(5):4428. doi: 10.3390/ijms24054428.
7
Individuals with bipolar disorder have a higher level of uric acid than major depressive disorder: a case-control study.双相情感障碍个体的尿酸水平高于重性抑郁障碍：一项病例对照研究。
Sci Rep. 2021 Sep 15;11(1):18307. doi: 10.1038/s41598-021-97955-4.
8
Pathways and Mechanism of Caffeine Binding to Human Adenosine A Receptor.咖啡因与人腺苷A受体结合的途径与机制
Front Mol Biosci. 2021 Apr 27;8:673170. doi: 10.3389/fmolb.2021.673170. eCollection 2021.
9
Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases.聚焦于腺苷受体作为人类疾病的潜在靶向治疗。
Cells. 2020 Mar 24;9(3):785. doi: 10.3390/cells9030785.
10
Purinergic system in psychiatric diseases.嘌呤能系统与精神疾病。
Mol Psychiatry. 2018 Jan;23(1):94-106. doi: 10.1038/mp.2017.188. Epub 2017 Sep 26.
本文引用的文献
1
Early expression of a novel nucleotide receptor in the neural plate of Xenopus embryos.非洲爪蟾胚胎神经板中一种新型核苷酸受体的早期表达。
J Biol Chem. 1997 May 9;272(19):12583-90. doi: 10.1074/jbc.272.19.12583.
2
Receptors responsive to extracellular pyrimidine nucleotides.对细胞外嘧啶核苷酸有反应的受体。
Trends Pharmacol Sci. 1997 Mar;18(3):83-6. doi: 10.1016/s0165-6147(96)01035-8.
3
4
The selective adenosine A2A receptor antagonist SCH 58261 discriminates between two different binding sites for [3H]-CGS 21680 in the rat brain.选择性腺苷A2A受体拮抗剂SCH 58261可区分大鼠脑中[3H]-CGS 21680的两个不同结合位点。
Naunyn Schmiedebergs Arch Pharmacol. 1996 Oct;354(4):539-41. doi: 10.1007/BF00168448.
5
Characterization and chromosomal localization of a human P2X receptor from the urinary bladder.膀胱中一种人类P2X受体的特性及染色体定位
Recept Channels. 1995;3(4):283-9.
6
Cloning OF P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels.P2X5和P2X6受体的克隆以及ATP门控离子通道扩展家族的分布与特性
J Neurosci. 1996 Apr 15;16(8):2495-507. doi: 10.1523/JNEUROSCI.16-08-02495.1996.
7
Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor.人类P2Y1嘌呤受体的第二信使级联特异性和药理学选择性
Br J Pharmacol. 1996 May;118(1):167-73. doi: 10.1111/j.1476-5381.1996.tb15381.x.
8
Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells.从人红白血病细胞中克隆一种新型P2嘌呤受体
J Biol Chem. 1996 Aug 2;271(31):18363-7. doi: 10.1074/jbc.271.31.18363.
9
A novel G protein-coupled P2 purinoceptor (P2Y3) activated preferentially by nucleoside diphosphates.一种新型的G蛋白偶联P2嘌呤受体（P2Y3），优先被二磷酸核苷激活。
Mol Pharmacol. 1996 Aug;50(2):258-65.
10
Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors.大鼠海马体和大脑皮层中存在与纹状体A2A受体不同的腺苷A2A受体激动剂[3H] CGS 21680的高亲和力结合位点的证据。
Naunyn Schmiedebergs Arch Pharmacol. 1996 Feb;353(3):261-71. doi: 10.1007/BF00168627.
Zotero 插件